ArticlePloS one2018
Role of economic evidence in coverage decision-making in South Korea.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Exploring trends of cost-effectiveness thresholds in South Korea: systematic review of pharmacoeconomic evaluations since introduction of the positive list system.Cost effectiveness and resource allocation : C/E · 2026Review
- Influence of clinical benefit and cost-effectiveness on reimbursement decisions for lung cancer drugs in Spain.Cost effectiveness and resource allocation : C/E · 2026Article
- Real-World Cost-Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure With Reduced Ejection Fraction in Korea.Korean circulation journal · 2025Article
- A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries.Applied health economics and health policy · 2024Review
- Expanding access to high-cost medicines under the Universal Health Coverage scheme in Thailand: review of current practices and recommendations.Journal of pharmaceutical policy and practice · 2023Article
- A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England.Applied health economics and health policy · 2023Article
- Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service.PharmacoEconomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe South Korean government required the submission of economic evidence when it implemented the Positive-List System in December 2006. This study investigates the key factors that influenced actual public insurance reimbursement decisions, including the role of economic evidence, after 10 years of decision practice under compulsory health technology assessment (HTA) for new drugs.
methodLogistic regression analysis was used to estimate the impact of the variables involved, including cost-effectiveness ratio as a key variable, on reimbursement decisions. The latter were defined as "yes" or "no" at a submitted price and indication. Only cases (n = 91) that present a cost-effectiveness ratio, and that have been reviewed based on this ratio from January 2007 to December 2016, were included in the analysis.
resultsCases with higher cost-effectiveness ratios were less likely to be accepted. In addition, drugs that were used to treat severe diseases and drugs with no substitute were more likely to be recommended. The probability of acceptance declined along with the level of uncertainty in the submitted evidence. The acceptance rate for severe-disease drugs has increased since 2013, when the government introduced several policies that lowered the existing barriers to positive reimbursement. However, such an increase was not statistically significant.
conclusionsCost-effectiveness is one of the most influential factors in drug-reimbursement decisions. However, inclusion of other explanatory variables, in addition to the cost-effectiveness ratio, predicted the results of decisions more accurately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.